|  |  |
| --- | --- |
| **Baseline** |  |
| **Date of birth** (dd-mm-åååå) |  |
| **Including country+centre** | Oslo University Hospital, Norway🗆Stavanger University hospital, Norway🗆 |
| **Dato for signert samtykke** (dd-mm-åååå) |  |
| **BRCA ½ mutasjonsstatus**: (location, type of deletion or duplication etc.) |  |
| **Gjennomgang av inkl. Og eksklusjonskriterier** (se eget skjema) | Utført 🗆 |
| **Fysisk undersøkelse**OBS! Skal være gjort i løpet av de siste 6 mnd | **Dato:****Type undersøkelse:** * TVA UL 🗆
* CA-125 🗆
* HE4 🗆
* Other 🗆
 |
| **Dersom TVA UL – hva viste denne?** | * Endometrium:
* Myometrium:
* Tubes:
* Ovary right:
* Ovary left:
* Free intraperitoneal fluid:
* Conclusion of ultrasound:
 |
| **Dersom CA-125- hva var resultatet?** |  |
| * CA-125 within range of normal value in your clinic?
 | Yes 🗆 No 🗆 |
| **Dersom HE4- hva var resultatet?** |  |
| **Dersom undersøkelse var Other:*** Type of other examination
* Conclusion of other physical examination
 |  |
| **Pasientens valg av operasjon:**(bør avklares i løpet det første året etter signert samtykke) | * Salpingo-oophorectomy 🗆
* Salpingo-oophorectomy + hysterectomy 🗆
* Salpingectomy🗆
* Salpingectomy + hysterectomy 🗆
* Other 🗆 : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
 |
| **Spørreskjema fylt ut** **(OBS! Dato for utfylling må være etter signert samtykke!)** |  |
| **Dato og signatur av lege som har vurdert pasienten** |  |

|  |  |  |
| --- | --- | --- |
| **Inklusjonskriterier** **(Protocol version 1.15)** | **Yes** | **No** |
| 1. **Patient has a documented germline mutation in the BRCA1, BRCA2, BRIP1, RAD51C and/or RAD51D gene**
 |  |  |
| 1. **Patient has a documented germline mutation in the following gene**

BRCA1 🗆 BRCA2 🗆 BRCA1+2🗆 |  |  |
| 1. **BRCA1 mutation carrier is between 25 and 40 years old**

**BRCA2 mutation carrier is between 25 and 45 years old** |  |  |
| 1. **Patient is premenopausal**
 |  |  |
| 1. **Patient has completed childbearing**
 |  |  |
| 1. **Patient still has at least one Fallopian tube**
 |  |  |
| 1. **Patient signed informed consent**
 |  |  |
| **Eksklusjonskriterier (Protocol version 1.15)** | **Yes** | **No** |
| 1. **Patient is currently postmenopausal, either due to natural menopause or to (cancer) treatment**)
 |  |  |
| 1. **Patient wishes to have second stage oophorectomy within 2 years of salpingectomy (in case of RRS with delayed RRO)**
 |  |  |
| 1. **Patient has already had prior bilateral salpingectomy**
 |  |  |
| 1. **Patient has a personal history of ovarian, Fallopian tube or peritoneal cancer**
 |  |  |
| 1. **Patient shows evidence of any malignant disease at enrollment**
 |  |  |
| 1. **Patient is currently being treated for any malignant disease**
 |  |  |
| 1. **Patient is legally incapable**
 |  |  |

**Jeg har vurdert at pasienten oppfyller alle krav til deltagelse i TUBA studien:**

**Dato:**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Signatur:**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Rolle i studien:**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_